Herbal formulations of carnivorous plants and methods for treating inflammation

ABSTRACT

Formulations and methods for treating inflammation using pitcher plants are described herein. The pitcher plant is made into herbal preparations, such as tinctures and infused solutions. The herbal preparation of the pitcher plant can be combined with vitamins, minerals, glutathione, solutions, and other plant preparations, such as a hemp plant preparation containing cannabidiol, to make a topical formulation. Administering the formulation to a subject can reduce and treat inflammation.

CROSS-REFERENCE

This application is a continuation-in-part and claims benefit of U.S.patent application Ser. No. 15/420,374, filed on Jan. 31, 2017, which isa continuation-in-part and claims benefit of U.S. patent applicationSer. No. 14/990,107, filed on Jan. 7, 2016, which is acontinuation-in-part and claims benefit of U.S. patent application Ser.No. 13/309,144, filed on Dec. 1, 2011, which is a non-provisional ofU.S. Provisional Patent Application No. 61/418,692, filed Dec. 1, 2010,and U.S. Provisional Patent Application No. 61/448,824, filed Mar. 3,2011, the specification(s) of which is/are incorporated herein in theirentirety by reference.

U.S. patent application Ser. No. 14/990,107 is also acontinuation-in-part and claims benefit of U.S. patent application Ser.No. 14/305,933, filed on Jun. 16, 2014, which is a non-provisional ofU.S. Provisional Patent Application No. 61/835,741, filed Jun. 17, 2013,the specification(s) of which is/are incorporated herein in theirentirety by reference.

U.S. patent application Ser. No. 14/990,107 is also acontinuation-in-part and claims benefit of U.S. patent application Ser.No. 14/306,581, filed on Jun. 17, 2014, which is a non-provisional ofU.S. Provisional Patent Application No. 61/835,749, filed Jun. 17, 2013,the specification(s) of which is/are incorporated herein in theirentirety by reference.

FIELD OF THE INVENTION

The present invention features formulations and methods of treatmentusing herbal formulations containing carnivorous plants, in particular,pitcher plants such as Sarracenia flava and Sarracenia purpurea.

BACKGROUND OF THE INVENTION

Historical data on uses of the pitcher plant spp. (i.e. Sarracenia spp.)demonstrate efficacy as a digestive aid and anti-viral (webmd.com,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302891/), having beenemployed as a medicine in early pharmacies, but never studied as to theexact effect on the immune system. However, work done on the presentinvention has identified that the carnivorous plant(s), Sarracenia flavaand Sarracenia purpurea (pitcher plant) and mixed hybrids or relatedspecies thereof, have the capability to decrease and stabilizefibrinogen levels, and do so quite dramatically.

Fibrinogen is a precursor acute-phase reactant protein produced by theliver in response to signals of systemic circulating cytokines, possiblyas an effort to stimulate a healing reaction within the immune system.It is involved in the creation of clots, atherosclerosis, andgeneralized inflammation. In the systemic circulation, it gets convertedto fibrin, which the present invention has determined can behomeostatically used by fibroblast and myofibroblast cells to heal orbuild tissues. Excess fibrinogen increases inflammation, cancer andover-deposition of tissues, such as scar tissues. Fibroblast andmyofibroblast activities are regulated by proteins called fibroblastgrowth factors (FGF), of which there are 23 identified currently(Mueller and Fusenig 2011 and Baird and Klagsbrun 1991). These growthfactors are dependent on the presence of glutathione, which are foundwithin the growth factors.

SUMMARY

The present invention features a composition comprising an herbalpreparation of carnivorous plants, such as pitcher plants. It issurprisingly discovered that the present composition is effectiveagainst diseases that manifest as a result of the deleterious effects ofinflammation and cancerous cells.

During the course of the invention, it was discovered that current lab“normals” for fibrinogen may indeed be flawed. For example, some labsset lab normals as 193-507 mg/dL and physicians read that as saying theclotting pathways are normal and working fine, and below 193 mg/dL meansthe patient will start to bleed out. Without wishing to limit theinvention to a particular theory or mechanism, the present invention hasdetermined that fibrinogen is healthy and ideal when levels are within165-225 mg/dL, which is defined herein as “homeostatic levels”, in orderfor the patient to live free of inflammatory symptoms. This range can bereached when pitcher plant preparations of the present invention areadministered orally. Above 225 mg/dL indicates that the patient may bestruggling with a systemic inflammatory process or cancer. For example,tumors tend to start developing once the fibrinogen levels surpass 225mg/dL. Fibrinogen levels over 225 and into the 300 s and above cancreate excess fibrin, which the body can use to make scar tissue. Thisfibrin may also be in the tissues of any disease, i.e. cancer,autoimmune conditions, blockages, etc.

During the course of the invention, it was revealed that fibrinogenlevels may be sensitive and can rapidly increase from exposure to smallamounts of stress or even processed sugars in the diet. Each of thesepatients also struggled with inflammatory or cancer-related conditionsincluding, but not limited to, multiple sclerosis, arthritis, cancer, orautoimmune conditions. It is possible that the body can manufacturefibrinogen immediately should the need arise, such as for clotting.Moreover, it is a possibility that people may suffer from medicalconcerns because their fibroblasts are constantly responding tocirculating inflammation, which means that these fibroblasts cells areconstantly trying to keep other cells and tissues healthy.

Like fibrinogen, fibroblast growth factors (FGF) have lab normals thatare currently not established, and are insignificant if they appear onthe lab. There are 23 known growth factors that can signal cells whattissue to heal or maintain. The growth factors are dependent onglutathione and must have vitamins A and D and magnesium in theextracellular matrix around them in order to signal cells to heal.

Currently, FGF-23 is the only one that can be checked in conventionallabs, its range being 44-215 Ru/mL. Without wishing to limit the presentinvention to a particular theory or mechanism, the present invention hasfound that FGF-23 levels below 99 Ru/mL indicate that the patient is a“slow healer”. The patient is chronically sick and does not improveeasily despite receiving treatments such as chemotherapy and commonneutraceuticals. Chronic diseases are likely to develop and set in tothe patient. Further, the patient does not get well overall and tends tostay sick, and may likely need medication, surgery, etc. FGF-23 levelsfrom 100-199 Ru/mL indicate that the patient is a “fast healer”. FGF-23levels above 200 could indicate a health condition such as cancer oracute inflammatory conditions. At these levels, the body is trying toheal something but is unable to do so.

Current medical standards classify high FGF-23 levels to be harmfulbecause the increase in fibroblast growth factors can signify that adisease or disorder, such as cancer, is secreting them to proliferate.In the case of cancer, since the tumors produce fibroblast growthfactors as the cell is dying, an oncologist would attempt to decreaseglutathione, thereby decreasing and inhibiting fibroblast growth factorsproduction in order to inhibit the tumors. It has been surprisinglydiscovered that these current medical standards are wrong.

Without wishing to limit the invention to a particular theory ormechanism, the present invention has surprising discovered that the bodyis increasing FGFs in an effort to heal. It is believed that the diseaseis producing what it needs to stimulate healing, yet current medicalpractices attempt to inhibit this. For example, by increasing fibroblastgrowth factors production, the tumors can shrink and heal. Thecomposition of the present invention is capable of increasing FGF levelsvia administering injections of a composition of the present invention,and decreasing fibrinogen levels to homeostatic conditions viaadministering oral composition of the present invention, therebytreating the disease. Clearly, current medical practices teach away fromthe concept of increasing fibroblast growth factors production as taughtin the present invention.

Immune cells, or lymph cells, can circulate within the body in a rhythm.Fibroblasts cells can be found in the lymph fluid. Current medicalstandards teach that minimal blood supply or lack thereof in blood flowto the tissue may be the reason for why the tissue does not heal well.Without wishing to limit the invention to a particular theory ormechanism, the present invention reasons that if there were a lack ofblood flow to the tissue, then the fibroblast is collecting in thevicinity of the tissue. Hence, it is another objective of the presentinvention to stimulate fibroblast movement in order to promote healingof the tissue. For example, administering topical compositions of thepresent invention can stimulate movement of the fibroblast, as well astransport nutrients to the FGF and the fibroblast extra-cellular matrix.

According to one embodiment, the present invention features compositionsand methods of treating inflammation. The method may compriseadministering one or more injections of a therapeutically effectiveamount of a composition to fascia and ligaments surrounding a spine ofthe subject. The composition may comprise an herbal preparation of acarnivorous plant, such as a pitcher plant Sarracenia purpurea, at arange of about 1% to 99% volume of the composition, and a glutathione ata range of about 1% to 99% volume of the composition. The herbalpreparation of the carnivorous plant is effective for facilitatingtransmission of the glutathione to fibroblast growth factors. Moreover,the administering of the composition to the subject can increasefibroblast growth factors at measureable levels in the subject, andadjusts fibrinogen levels to homeostatic levels in the subject, therebyameliorating symptoms of the inflammation of the subject. Furthermore,the one or more injections are effective for stimulating movement andactivity of fibroblast cells via insertion of the injection needle(http://www.ncbi.nlm.nih.gov/pubmed/24593827). The composition mayfurther comprise supplements such magnesium, vitamin D, vitamin A, andglucosamine.

According to another embodiment, the present invention features oralcompositions and methods for decreasing fibrinogen levels to homeostaticlevels. The oral compositions may comprise the herbal preparation of thecarnivorous plant, such as the pitcher plant Sarracenia flava,Sarracenia purpurea, or hybrids thereof. Patients, when orallyadministered the composition, see a resolution of inflammatory symptomsvia a decrease in fibrinogen levels measureable in blood. Withoutwishing to limit the present invention to particular mechanism ortheory, the pitcher plant is surprisingly discovered to decreasefibrinogen levels to homeostatic levels, as shown by pre- andpost-patient labs upon prescribed oral use of the pitcher plant, therebyreducing symptoms of inflammation due to the decrease in fibrinogenlevels, and increasing pain-relieving effects.

In yet a further embodiment, the present invention features topicalcompositions comprising the herbal preparation of the carnivorous plant,such as the pitcher plant Sarracenia flava, Sarracenia purpurea, orhybrids thereof. Without wishing to limit the present invention toparticular mechanism or theory, the pitcher plant is surprisinglydiscovered to stimulate movement of fibroblasts. Moreover, the pitcherplant has a transdermal effect, i.e. the pitcher plant is amphiphilicsuch that it can carry substances, such as magnesium, which is insolublein fats, into and through the skin.

It is known that botanicals and nutraceuticals (supplements) havesynergistic effects when combined together, for example with regards tothe use of Chinese herbs (Xu et al. 2014 and Yang et al. 2009).According to embodiments of the present invention, the composition canbe combined with antioxidants such as berries or glutathione, fibroblastprotectors such as extracts of orchids, fibroblast motility enhancerssuch as extracts of lily, immune modulators such as curcumin or blackcohosh extracts, and cytoprotectors such as astragalus. The pitcherplant may also be combined with bases such as coconut oil, cleanserssuch as lye for saponification processes, and astringents such as witchhazel.

In some aspects, the present invention may feature an anti-inflammatoryformulation comprising about 0.1-99% wt/vol of a hemp plant preparationcontaining cannabidiol, and one or more components selected from a groupconsisting of a carnivorous plant preparation, a mineral, an amino acid,and glutathione. In some embodiments, the hemp plant preparation maycomprise about 1-30% wt/vol of cannabidiol. In other embodiments, thehemp plant preparation may further comprise about 0.1-20% wt/vol oftetrahydrocannabinol. In some embodiments, the formulation may besuitable for oral administration, topical administration, oradministration by injection. For example, the formulation may be in aform of a lotion, cream, oil, gel, an oral tincture, or an injectable.

Each of the one or more components may be present in an amount that isat least 0.001% wt/vol of the formulation. For instance, the formulationmay comprise at least 0.001% wt/vol of a mineral. In some embodiments,the mineral may be magnesium, manganese, selenium, zinc, or acombination thereof. In other embodiments, the formulation may compriseat least 0.001% wt/vol of an amino acid such as, for example, cysteine.In yet other embodiments, the formulation may comprise at least 0.001%wt/vol of glutathione. In some other embodiments, the formulation mayfurther comprise one or more vitamins such as, for example, vitamin D,niacin, folic acid, or a combination thereof. The one or more vitaminsmay be at least 0.001% wt/vol of the formulation.

In one embodiment, the formulation may comprise at least 0.001% wt/volof a carnivorous plant preparation. The carnivorous plant preparationmay be derived from Sarracenia flava, Sarracenia purpurea, or mixedhybrids thereof. In some embodiments, the carnivorous plant preparationmay comprise limonene.

According to other aspects, the anti-inflammatory formulation maycomprise about 0.1-99% wt/vol of a hemp plant preparation containingcannabidiol, at least about 0.1% wt/vol of a carnivorous plantpreparation, at least about 0.001% wt/vol of a mineral component, atleast about 0.001% wt/vol of an amino acid component, and at least about0.001% wt/vol of glutathione. The formulation may be in a form of alotion, cream, oil, gel, an oral tincture, or an injectable. In oneembodiment, the hemp plant preparation may comprise about 1-30% wt/volof cannabidiol. In another embodiment, the hemp plant preparation mayfurther comprise about 0.1-20% wt/vol of tetrahydrocannabinol. In someembodiments, the carnivorous plant preparation is derived fromSarracenia flava, Sarracenia purpurea, or mixed hybrids thereof. Thecarnivorous plant preparation may comprise limonene. In one embodiment,the mineral component may comprise magnesium, manganese, selenium, zinc,or a combination thereof. For example, the mineral component maycomprise magnesium, selenium, and zinc with the magnesium andglutathione each present in amounts greater than each individual amountof selenium, zinc, and the amino acid component. In some embodiments,the amino acid component is cysteine.

As a non-limiting example, the anti-inflammatory formulation may be atopical formulation comprising about 0.1-99% wt/vol of a hemp plantpreparation containing cannabidiol, at least about 0.1% wt/vol of acarnivorous plant preparation, at least about 0.001% wt/vol ofmagnesium; at least about 0.001% wt/vol of glutathione, at least about0.001% wt/vol of selenium, at least about 0.001% wt/vol of zinc, and atleast about 0.001% wt/vol of cysteine. Preferably, the magnesium andglutathione are present in amounts greater than the amounts of selenium,zinc, and cysteine. The topical formulation may further comprise atleast about 0.001% wt/vol of managanese. In other embodiments, thetopical formulation may further comprise at least about 0.001% wt/vol ofone or more vitamins such as, for example, vitamin D, niacin, folicacid, or a combination thereof.

In some other aspects, the present invention may feature a topicalformulation for treating inflammation comprising about 0.1-99% wt/vol ofa carnivorous plant preparation, and at least about 0.001% wt/vol ofglutathione. In one embodiment, the carnivorous plant preparation isderived from Sarracenia flava, Sarracenia purpurea, or mixed hybridsthereof. The topical formulation may contain limonene derived from thecarnivorous plant. In some embodiments, the formulation may furthercomprise one or more of the following: at least about 0.1% wt/vol of ahemp plant preparation containing about 1-30% wt/vol of cannabidiol, atleast about 0.001% wt/vol of minerals, or at least about 0.001% wt/volof glutathione. In other embodiments, the formulation may furthercomprise one or more of the following: at least about 0.001% wt/vol ofamino acids, at least about 0.001% wt/vol of vitamins, or at least about0.001% wt/vol of glucosamine.

Any feature or combination of features described herein are includedwithin the scope of the present invention provided that the featuresincluded in any such combination are not mutually inconsistent as willbe apparent from the context, this specification, and the knowledge ofone of ordinary skill in the art. Additional advantages and aspects ofthe present invention are apparent in the following detaileddescription.

BRIEF DESCRIPTION OF FIGURES

FIG. 1 shows an MRI image of a brain. The white-colored portion of thebrain indicates cancer.

FIG. 2 shows MRI images of the same brain taken three months later. Thepatient was administered spinal injections comprising the composition ofthe present invention during those three months.

DESCRIPTION OF PREFERRED EMBODIMENTS

According to the International Carnivorous Plant Society(www.carnivorousplants.org), a “carnivorous plant” is a predatory plantthat obtains its nutrients by trapping and killing prey. A carnivorousplant has the following features: 1. the plant captures and kills prey;2. the plant has some mechanism to digest the prey; and 3. the plantabsorbs the nutrients from the prey. Some non-limiting examples ofcarnivorous plants include species from the genus Sarracenia, Nepenthes,Dionaea, Utricularia, Heliamphora, Cephalotus, and Drosera. Thepreferred carnivorous plants of the present invention are pitcherplants, namely, Sarracenia flava and Sarracenia purpurea. Since theseplants can readily interbreed, the carnivourous plants can includehybrids thereof.

As used herein, the term “extract” is defined as a separation of thebeneficial (medicinal) components of an herb from the fibrous, lessuseful part of the plant. Extracts can be in a liquid or powdered form.

As used herein, the term “infuse” is defined as a procedure ofwithdrawing nutritive compounds of an herb into a medium, and allowingthem to linger in the medium for a period of time to allow for thetransfer of herbal extracts into the medium. An “infused solution” isthe resulting solution with the nutritive compounds.

As used herein, the term “tincture” is defined as a heavily concentratedextract made by placing chopped fresh or dried herbs into a containerand covering them with a solvent. The mixture is then sealed and allowedto macerate for several weeks.

As used herein, an “herbal preparation” or a “plant preparation” may bean extract, tincture, or infused solution made or prepared from an herbor plant. The herbal preparation contains the active components from theherb or plant. For example, the herbal preparation of a pitcher plantmay be a pitcher plant extract, tincture, or infused solution. Anotherexample is a curcumin preparation derived from turmeric, or a curcumintincture, extract or infused solution. An Orchidaceae plant preparationmay be an orchid extract, tincture, or infused solution derived from anyOrchidaceae species. A Lilium plant preparation may be a lily extract,tincture, or infused solution derived from any Lilium species, such as alily root extract prepared from Lilium candidum. A Rosa plantpreparation may be a rose extract, tincture, or infused solution derivedfrom any Rosa species, such as absolute rose oil prepared from Rosadamascena. A hemp plant preparation may be an extract, tincture, orinfused solution containing cannabidiol (CBD), such as CBD oil.

In some embodiments, the CBDs may be derived from a hemp plant or otherplant containing CBDs. For example, the CBD oil may comprise a hemp oilextract in a carrier oil, such as coconut oil or olive oil. The hempplant preparation may comprise about 1% to about 50% wt/vol of CBDs. Forexample, the hemp plant preparation may comprise about 3% to about 25%wt/vol of CBDs. As another example, the hemp plant preparation maycomprise about 20% to about 50% wt/vol of CBDs. In other embodiments,the hemp plant preparation may comprise about 10 mg to about 75 mg CBDsper ml of CBD oil. For example, the hemp plant preparation may compriseabout 25 mg to about 50 mg CBDs per ml of CBD oil.

In other embodiments, the hemp plant preparation may further comprisetetrahydrocannabinol (THC). In some embodiments, the hemp plantpreparation may comprise about 0.1-0.3% wt/vol of THC. In otherembodiments, the hemp plant preparation may comprise about 0.3-1% wt/volof THC, or about 1-5% wt/vol of THC, or about 5-10% wt/vol of THC, orabout 10-15% wt/vol of THC, or about 15-20% wt/vol of THC. In yet otherembodiments, the hemp plant preparation may comprise more than about 20%wt/vol of THC.

A pitcher plant component is extracted from the pitcher plant. As usedherein, a “pitcher plant component”, or alternatively, an “activecomponent” is defined as the beneficial (medicinal) plant parts/materialof pitcher plant. For instance, the herbal preparation of the pitcherplant may be an oil infused with the pitcher plant active component. Thepitcher plant active component may comprise one or more compounds. Forexample, the pitcher plant component may include limonene.

As a non-limiting example of extracting the active components from thepitcher plant, in some embodiments, the pitcher plant is cut into smallpieces, pulverized, mashed, or chopped. The pitcher plant pieces areplaced in a non-reactive storage container, such as glass or plastic. Arequired amount of liquid, such as water, alcohol, or vinegar, is addedto the storage container. The mixture is set aside and allowed toincubate for a period of time. The pitcher plant's active componentstransfer from the plant material into the liquid. After the incubationperiod is over, any plant material solids are separated from the liquid.The resulting liquid is the pitcher plant tincture. In anotherembodiment, a pitcher plant extract is prepared by dehydrating thepitcher plant material and pulverizing or grinding the plant materialinto a powder.

As used herein, “weight/vol” is defined as a % concentration of unitweight or mass to unit volume. For example, a % w/v may refer to aconcentration in g/ml.

As used herein, the term “supplement” are generally understood include,but are not limited to, vitamins, minerals, fiber, fatty acids, aminoacids and amine derivatives. As used herein, the term “minerals” may becategorized into two kinds of minerals: macrominerals and traceminerals. Macrominerals include, but are not limited to, calcium,phosphorus, magnesium, sodium, potassium, chloride and sulfur. Traceminerals include, but are not limited to, iron, manganese, copper,iodine, zinc, cobalt, fluoride and selenium. Examples of vitaminsinclude, but are not limited to, retinoic acid (Vitamin A), Vitamin B3in the form of niacin (nicotinic acid), niacinamide (nicotinamide) orinositol hexanicotinate, folic acid or folate, vitamin B-complex,vitamin C, vitamin D, vitamin E, and vitamin K. Non-limiting examples offatty acids include phosphocholine, phosphytidylcholine, andphosphytidylserine. Non-limiting examples of amino acids includecysteine and arginine, such as L-cysteine and L-arginine. Examples ofamine derivatives include, but are not limited to, glucosamine.

For example, vitamin C and/or vitamin C derivatives include fatty acidesters of ascorbic acid, particularly ascorbyl palmitate. As anotherexample, vitamin E and/or derivatives of vitamin E include tocotrienoland/or tocotrienol derivatives.

In some embodiments, examples of pharmaceutically acceptable salts ofmagnesium that may be used in the topical compositions describe hereininclude, but are not limited to, magnesium oxide, magnesium carbonate,magnesium chloride, magnesium sulfate, magnesium phosphate, magnesiumbicarbonate, magnesium glycinate, magnesium aspartate, magnesiumglutamate, magnesium adipate, magnesium citrate, magnesium orotate,magnesium taurate, magnesium lysinate, and the like. Examples ofpharmaceutically acceptable salts of zinc that may be used in thetopical compositions describe herein include, but are not limited to,zinc chloride, zinc oxide, zinc sulfate, and the like. Examples ofpharmaceutically acceptable salts of calcium that may be used in thetopical compositions describe herein include, but are not limited to,calcium acetate, calcium carbonate, calcium chloride, calcium citrate,and calcium gluconate.

In other embodiments, the selenium mineral may be in an organic orinorganic form. For example, an organic form of selenium that may beused in accordance with the present invention is selenomethionine.Inorganic forms of selenium include sodium selenite and sodium selenate.

Any of the minerals disclosed herein may be used in the form ofpharmaceutically acceptable salts. As used herein, “pharmaceuticallyacceptable” is meant that which is useful for the preparation of apharmaceutical composition and is generally safe, non-toxic and neitherbiologically nor otherwise undesirable and which is acceptable forveterinary use as well as in human pharmaceutics.

By “pharmaceutically acceptable salts” of a compound is meant saltswhich are pharmaceutically acceptable as defined herein and which havethe desired pharmacological action of the parent compound. Such saltscomprise useful salts are acid addition salts, which are formed bypharmaceutically acceptable free acids. The acid addition salts areobtained from inorganic acid, such as hydrochloric acid, nitric acid,phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid,nitrous acid or phosphorous acid and the like; or formed withpharmaceutically acceptable organic acids, such as aliphatic mono- anddicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates,alkanedioates, aromatic acids, aliphatic and aromatic sulphonic acids,acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid,citric acid, ethane-sulfonic acid, fumaric acid, glucoheptonic acid,gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid,2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid,mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonicacid, propionic acid, salicylic acid, succinic acid,dibenzoyl-L-tartaric acid, tartaric acid, p-toluenesulfonic acid,trimethylacetic acid, trifluoroacetic acid and the like. Suchpharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate,sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate,dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide,iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate,formate, isobutyrate, caprate, heptanoate, propiolate, oxalate,malonate, succinate, suberate, sebacate, fumarate, maleate,butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate,methylbenzoate, dinitro benzoate, hydroxybenzoate, methoxybenzoate,phthalate, terephthalate, benzene sulfonate, toluene sulfonate,chlorobenzene sulfonate, xylenesulfonate, phenyl acetate,phenylpropionate, phenyl butyrate, citrate, lactate, hydroxybutyrate,glycolate, malate, tartrate, methane sulfonate, propane sulfonate,naphthalene-1-sulfonate, naphthalene-2-sulfonate or mandelate.

In other embodiments, the pharmaceutically acceptable salts may comprisethe addition salts of pharmaceutically acceptable bases formed when anacid proton contained in the parent compound is either replaced by ametal ion e.g. an alkaline metal ion, an alkaline-earth metal ion oraluminium ion; or coordinated with a pharmaceutically acceptable organicor inorganic base. Acceptable organic bases include diethanolamine,ethanolamine, N-methylglucamine, triethanolamine, tromethamine and thelike. Acceptable inorganic bases include aluminium hydroxide, calciumhydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.

As used herein, “inflammation” is a biological protective response inwhich the body attempts to remove harmful stimuli, including, damagedcells, irritants, or pathogens, in order to begin the healing process.Inflammation is a component or symptom of numerous diseases andconditions, including but not limited to, cancer, arthritis such asosteoarthritis and osteoporosis, diabetes herniated discs, lesions suchas brain lesions, skin lesions, wounds, ulcers, tumors, and sores, skindisorders such as eczema, gastrointestinal disorders such as irritablebowel syndrome, psychological disorders such as depression and anxiety,and cognitive decline such as Alzheimer's and dementia. Symptoms ofinflammation include pain, heat, redness, swelling, scar tissue, andloss of function.

As used herein, the terms “administering” or “administer” is defined asthe introduction of a substance (composition) into cells in vitro orinto the body of an individual in vivo and includes topical, oral,nasal, ocular, rectal, vaginal and parenteral routes. The composition ofthe present invention may be administered via any route ofadministration, including but not limited to topical, subcutaneous,intramuscular, intravenous, intradermal, or orally. For example, thecomposition can be administered by needle injections into the fascia andligaments surrounding the spine. As known to one of ordinary skill inthe art, ligaments are fibrous bands of connective tissue that attach tobone. For example, the supraspinous ligament is a ligament that attachesthe tip of each spinous process to the other. The spinous process is abony projection off the posterior (back) of each vertebra. Otherexamples of ligaments include the nuchal ligament, which is a ligamentat the back of the neck that is continuous with the supraspinousligament, and the interspinous ligaments, which are ligaments that jointhe spinous processes along their adjacent borders. As known to one ofordinary skill in the art, the fascia is a strong sheath-like connectivetissue. For example, the thoraco-lumbar fascia, or lumbodorsal fascia,is a tough, membranous connective tissue covering the muscles of theback of the trunk. In the lumbar region, the lumbodorsal fascia isattached, medially, to the spinous processes of the thoracic vertebrae.

As defined herein, the terms “treating” or “treatment” of a conditionincludes: (1) preventing the condition, i.e., causing the clinicalsymptoms of the condition not to develop in a mammal that may be exposedto or predisposed to the condition but does not yet experience ordisplay symptoms of the condition; (2) inhibiting the condition, i.e.,arresting or reducing the development of the condition or its clinicalsymptoms; or (3) ameliorating or relieving the condition, i.e., causingregression of the condition or its clinical symptoms. The compositioncan be administered to treat inflammation. As used herein, the terms“treat” or “treatment” refer to both therapeutic treatment orpreventative measures, wherein the object is to prevent or slow down(lessen) an undesired physiological change or disorder, such as thedevelopment or worsening of inflammation. For purposes of thisinvention, beneficial or desired clinical results include, but are notlimited to, alleviation of symptoms, diminishment of extent of disease,stabilized (i.e., not worsening) state of disease, delay or slowing ofdisease progression, amelioration or palliation of the disease state,and remission (whether partial or total), whether detectable orundetectable. “Treatment” can also mean prolonging survival as comparedto expected survival if not receiving treatment. Those in need oftreatment include those already with the condition or disorder as wellas those prone to have the condition or disorder or those in which thecondition or disorder is to be prevented or onset delayed. Optionally,the patient may be identified (e.g., diagnosed) as one suffering fromthe disease or condition (e.g., any disease or condition that results ininflammation) prior to administration of the composition of theinvention.

As used herein, Cytenssic means “cell essence, and Cytenssic therapy isa treatment developed in the present invention. The principle ofCytenssic therapy is that the body is able to heal itself via thefibroblast growth factors, and any other related growth factor. The baseformulation of Cytenssic therapy is the carnivorous plant andglutathione. Minerals, vitamins, and other anti-cancer herbs can beadded to the base formulation. When the FGF levels are increased,inflammation is reduced and the body is able to heal and rid itself ofthe disease.

As used herein, the term “therapeutically effective amount” refers to anamount of a compound, i.e. the composition, effective to treat acondition, disease or disorder in a subject. In the case ofinflammation, the therapeutically effective amount of the presentcomposition may reduce (i.e., slow to some extent and preferably stop)inflammation, and/or relieve, to some extent, one or more of thesymptoms associated with a disorder or disease. The “therapeuticallyeffective amount” will vary depending on the compound, the condition andits severity and body factors such as age, weight, etc., of the subjectto be treated.

As used herein, the term “homeostasis”, and derivatives thereof, refersto the ability to regulate variables such that conditions remain stableand relatively constant. For instance, when fibrinogen levels are athomeostasis, the levels are within the healthy range of 165-225 mg/dL,and maintained in that range, as discovered in the present invention.

As used herein, a “solution” is defined as is a homogeneous mixturecomposed of two or more substances. A “solute” is a substance dissolvedin another substance, known as a “solvent”.

As used herein, the terms “those defined above” and “those definedherein” when referring to a variable incorporates by reference the broaddefinition of the variable as well as any narrow and/or preferred, morepreferred and most preferred definitions, if any.

Preparing Pitcher Plant Tincture

In preferred embodiments, the herbal preparation of carnivorous plant isprepared from pitcher plant, such as a Sarracenia purpurea or aSarracenia flava plant. In alternative embodiments, a tincture may beobtained from other carnivorous plant tinctures. Some non-limitingexamples of carnivorous plants are the Drosera species, Dionaea species,and the Utricularia species.

A pitcher plant tincture is made using a “soak and press” technique. Asa non-limiting example, the pitcher plant tincture may be made from aSarracenia flava, Sarracenia purpurea, or hybrids thereof. (pitcherplant). For example, Sarracenia purpurea material is obtained,preferably from plants grown in the absence of pesticides, and thenchopped, forming a “chopped plant mixture”. The material may be theleaves, i.e. pitchers, of the plant. In some embodiments, during theharvesting process, the pitchers are cut at the base of the plant,leaving the rhizome. The pitchers may be cleaned such that all detritusand dirt are removed, and assayed for bacterial content (such assays arewell known to one of ordinary skill in the art). During the choppingprocess, the pitchers may be cut lengthwise and/or chopped into strips(e.g., about 1 to 2.5 inch strips). In some embodiments, during thechopping process, the strips may be placed in a blender/chopper.

The chopped plant material may be placed in a jar or container, e.g., aglass jar. Any appropriate container may be used, for example a glassjar. Clear jars may be used as well as other shaded containers such asamber glass jars. Liquid is added to the chopped plant material, e.g.,at a ratio of about 1 gram chopped plant material to about 2 mL liquid.The liquid may be, for example, an alcohol blend. In some embodiments,the liquid comprises an alcohol and water, e.g., distilled water. Forexample, the alcohol may be grain alcohol such as Everclear.

The liquid has a ratio of alcohol to water. In some embodiments, theratio is about 60:40 alcohol to water. In some embodiments, the ratio isabout 50:50 alcohol to water. In other embodiments, the ratio is about40:60 alcohol to water. In still other embodiments, the ratio is about30:70 alcohol to water. In some embodiments, the ratio is about 20:80alcohol to water. In other embodiments, the ratio is about 10:90 alcoholto water. In still other embodiments, the ratio is about 70:30 alcoholto water. In some embodiments, the ratio is about 80:20 alcohol towater. In other embodiments, the ratio is about 90:10 alcohol to water.As an example, in some embodiments, about 454 grams of chopped plantmaterial is placed in a jar, and about 908 mL of the liquid (with abouta 60/40 ratio of alcohol (Everclear) to distilled water) is added to thechopped plant material.

After the liquid is added to the chopped plant material, the containeris sealed. In some embodiments, the mixture is allowed to incubate foran incubation period, e.g., between about 1 to 2 days, between about 2to 7 days, between about 1 to 2 weeks, between about 2 to 3 weeks,between about 4 to 6 weeks, more than 6 weeks, etc. In some embodiments,the mixtures are stirred occasionally during the incubation period. Theincubation period, or a portion of the incubation period may featureplacing the container in a low-light or dark environment.

After the incubation period, the liquid is decanted off, e.g., with acoffee filter or vacuum. The resultant liquid is the pitcher planttincture, which may be stored and sealed, e.g., in amber glass bottles.

The following is a non-limiting example of making a Sarracenia tincture:

-   -   1. Cut the Sarracenia pitcher plants lengthwise and then chop        into 1-2½ inch strips.    -   2. Blend the plant material with a small amount of liquid. The        liquid is about a 60/40% blend of Everclear to distilled water.    -   3. Place the chopped herbs in glass jars in a quantity of about        454 grams.    -   4. Measure about 908 mL of a liquid of about 60/40% Everclear to        distilled water and poured over the chopped plant material.    -   5. Seal the jars and let sit for about 4 to 6 weeks in a dark        room.    -   6. Occasionally stir the jars.    -   7. After the plant material has sat for about 4 to 6 weeks, the        liquid is decanted off with a coffee filter or vacuum.    -   8. The resultant liquid is stored in amber glass bottles and        sealed.

Pitcher Plant Infused Solution

In some embodiments, a Sarracenia infused solution is made from aSarracenia tincture. The Sarracenia tincture is mixed with a solvent anddistilled for a period of time to remove the alcohol. In someembodiments, distilling the Sarracenia tincture and solvent mixtureinfuses the solvent with the Sarracenia component. In some embodiments,the solvent is oil or glycerin. In some embodiments, the oil is acarrier oil such as castor oil and coconut oil. When using oil as asolvent, the resulting solution is a Sarracenia infused oil.

In some embodiments, the ratio of Sarracenia tincture to solvent isbetween about 30:70 to 60:40. In other embodiments, the ratio ofSarracenia tincture to solvent is between about 30:70 to 40:60. In stillother embodiments, the ratio of Sarracenia tincture to solvent isbetween about 40:60 to 50:50. In some embodiments, the ratio ofSarracenia tincture to solvent is between about 50:50 to 60:40. In otherembodiments, the alcohol in the tincture is grain alcohol, such asEverclear.

In one embodiment, distilling the Sarracenia tincture and solventmixture comprises placing the Sarracenia tincture and solvent mixture ina storage container; capping the storage container with a cap having atleast one aperture and at least one tube, placing a tube second end in acollection container; heating the Sarracenia tincture and solventmixture to a temperature at about a boiling point of the alcohol tovaporize the alcohol; and collecting the alcohol vapors in thecollection container. In some embodiments, the period of time fordistilling the Sarracenia tincture and solvent mixture is between about1 to 3 hours, such as 1-2 or 2-3 hours. The temperature of distillationcan be about 75° C. and 90° C., such as about 75° C. and 80° C., 80° C.and 85° C., or 85° C. and 90° C. In some embodiments, a heat source forthe distillation process is a hot plate, a stove, or a burner.

The following is a non-limiting example of making a Sarracenia infusedsolution:

-   -   1. Measure about 500 mL of Sarracenia spp. tincture    -   2. Measure about 500 mL of solvent    -   3. Pour both into an Erlenmeyer flask.    -   4. Top the flask with a rubber stopper that has tubing coming        out of the stopper and into a large glass collection container.    -   5. Place the flask on a heat source, such as a hot plate.    -   6. Heat the flask containing the mixture on low or low-medium        heat for about 1-2 hours and monitor flask. As it heats, the        alcohol in the Sarracenia spp. tincture will evaporate off and        could blow off the rubber stopper if the pressure inside the        flask exceeds the evaporation. If this is the case, then lower        the heat.    -   7. After about 1-2 hours, the alcohol will be evaporated off and        the oil or liquid base will be completely infused with the        healing properties of the carnivorous plant.

Formulations and Methods of Treatment

The present invention features a treatment designed to stimulate ahealing response/cascade to circulating levels of inflammation byincreasing fibroblast growth factor levels while simultaneously bringingfibrinogen levels to homeostatic levels, therefore alleviating patientsymptoms related to pain and inflammation. As used herein, saidtreatment is referred to as “Cytenssic therapy”, in which Cytenssicmeans “cell essence”. This therapy utilizes various combinations offormulations that synergize the pitcher plant extracts, or othercarnivorous plants herein, with known antioxidants, anti-inflammatoryherbals, bases, injectables, nutraceuticals (supplements) or mixturesthereof. The mode of administration to the patient may be selected by aphysician of ordinary skill in the art.

Referring now to FIGS. 1-2, according to one embodiment, the presentinvention features a method of treating inflammation in a subject. Themethod may comprise administering one or more injections of atherapeutically effective amount of a composition to fascia andligaments surrounding a spine of the subject. Preferably, the one ormore injections may be administered at a depth of about ½ inch into theskin. For example, the one or more injections of the composition may beadministered into the Du Meridian acupuncture points, du14-2, using a 30g, ½ inch needle. In preferred embodiments, the composition may comprisean herbal preparation of a carnivorous plant, and a glutathione. In oneembodiment, the herbal preparation is at a range of about 0.1% to 99%volume of the composition. In another embodiment, the glutathione is ata range of about 0.1% to 99% volume of the composition. Without wishingto limit the invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for facilitatingtransmission of the glutathione to fibroblast growth factors. Moreover,the administering of the composition to the subject can increasefibroblast growth factors at measureable levels in the subject, andadjusts fibrinogen levels to homeostatic levels in the subject, therebyameliorating symptoms of the inflammation of the subject. Furthermore,the injections may be effective for stimulating movement of fibroblastcells. When utilizing the method described herein, after administeringthe injections, the fibroblast growth factors increases to high levelsuntil healing is accomplished. When the treatment is complete, the FGFlevels then decrease to FGF homeostatic levels in the 100-199 Ru/mLrange.

In some embodiments, the herbal preparation of the carnivorous plant isprepared from a pitcher plant, such as Sarracenia flava, Sarraceniapurpurea, and hybrids thereof. However, it is understood that anycarnivorous plant may be used for the herbal preparation.

In other embodiments, the composition may be administered at a dosage ofabout 8 to 20 cc every 4 weeks. For example, the composition may beadministered at about 9 cc, depending on the tolerance of the subject,and then increased at each subsequent dosage.

In one embodiment, the composition may further comprise one or moresupplements, at a range of about 0.1-99% vol of the composition,selected from a group consisting of vitamins, minerals, essential fattyacids, amino acids, and amine derivatives. The herbal preparation of thecarnivorous plant may be effective for facilitating transmission of theone or more supplements to the fibroblast growth factors. Examples ofvitamins include, but are not limited to, retinoic acid (Vitamin A),niacin, folic acid, vitamin B-complex, vitamin C, vitamin D, vitamin E,and vitamin K. Examples of minerals include, but are not limited to,calcium, phosphorus, magnesium, sodium, potassium, chloride, sulfur,iron, manganese, copper, iodine, zinc, cobalt, fluoride and selenium. Insome embodiments, the amine derivative may be glucosamine. In otherembodiments, the amino acid may be cysteine or arginine, such asL-arginine.

In a preferred embodiment, the supplement is magnesium and saltsthereof. Without wishing to limit the present invention to a particulartheory or mechanism, when the subject has low levels of magnesium,symptoms of the subject's disorder can flare. By increasing magnesiumlevels, the symptoms decrease and the subject starts to heal. Forexample, the composition in combination with magnesium chloride may beadministered to the subject by injection into or at the spine toincrease magnesium levels, thereby alleviating muscle pain, twitching,and spasms. In addition, the presence of pain can signal that thesubject has low levels of glutathione and/or magnesium. Hence, bycorrecting the glutathione and/or magnesium levels, the subject canexperience pain relief.

In yet another embodiment, the composition may further comprise athyroid hormone. For example, the composition in combination withthyroid hormone at a range of about 0.1-99% vol of the composition, i.e.about 5-15% vol of the composition, may be administered to the subjectby injection into or at the spine.

According to an exemplary embodiment, the composition may comprise theherbal preparation of a carnivorous plant at a range of about 0.1-99%vol of the composition, glutathione at a range of about 0.1-99% vol ofthe composition, magnesium at a range of about 0.1-99% vol of thecomposition, vitamin A at a range of about 0.1-99% vol of thecomposition, vitamin D at a range of about 0.1-99% vol of thecomposition, L-arginine at a range of about 1-99% vol of thecomposition, glucosamine at a range of about 0.1-99% vol of thecomposition, and a thyroid hormone at a range of about 0.1-99% vol ofthe composition.

In some embodiments, the composition may further comprise one or more ofthe following: aloe vera gel, glycerine, natural oils, an emulsifier,menthol crystals, berries, green tea extract, medicinal mushrooms,turmeric, ginger, viscum, burdock, devil's claw, boneset, valerian,skullcap, marshmallow root, mullein leaf, elecampane root, fennel seed,licorice root, old man's beard lichen, orange peel, osha root, wildcherry bark, propolis, ginkgo, poppy, polygonum, hops, passionflower,avena, and arnica.

In other embodiments, the composition may further comprise atherapeutically effective amount of one or more plant preparationsselected from a group consisting of an astragalus preparation, acurcumin preparation, a black cohosh preparation, an Orchidaceae plantpreparation, a Lilium plant preparation, a Sanguinaria canadensispreparation, a Rosa plant preparation, cannabidiol (CBD) derived from ahemp plant preparation and a berry preparation. The berry preparationmay be an antioxidant. The Orchidaceae plant preparation may be afibroblast protector. The Lilium plant preparation may be a fibroblastmotility enhancer.

In still other embodiments, the composition may further comprise one ormore solutions such as, for example, a witch hazel solution, a lyesolution, a salt solution, a carrier oil such as coconut oil, olive oil,castor oil, canola oil, sweet almond oil, apricot kernel oil, avocadooil, grapeseed oil, jojoba oil, sunflower oil, hemp seed oil, kukui nutoil, evening primrose oil, and a gelatin.

In further embodiments, the composition may further comprise one or bothof an adrenal formulation and an immune formulation. In one embodiment,the adrenal formulation may comprise withania at about 25-35% vol of theadrenal formulation, rhodiola at about 20-30% vol of the adrenalformulation, licorice at about 10-20% vol of the adrenal formulation,milky oats at about 5-15% vol of the adrenal formulation, ginseng atabout 5-15% vol of the adrenal formulation, gota kola at about 1-5% volof the adrenal formulation, and lemon balm at about 1-5% vol of theadrenal formulation. In another embodiment, the immune formulation maycomprise LIVIXIR at about 25-35% vol of the immune formulation,astragalus at about 10-20% vol of the immune formulation, elderberry atabout 5-15% vol of the immune formulation, hydrastis at about 5-15% volof the immune formulation, echinacea at about 5-15% vol of the immuneformulation, usnea at about 1-5% vol of the immune formulation, andinula at about 1-5% vol of the immune formulation.

In some embodiments, Cytenssic therapy may involve the administration ofa series of injections to the joint space, tendon, ligament, or muscle.A systemic effect is seen when a pitcher plant injectable is mixed withglutathione for injection into the spinal area, and placed via needlemanipulation in the tissue to be affected, such as a ligament, tendon,or any other kind of connective tissue surrounding the spine. Forexample, when the needle is placed at or near the joint space, it canaffect healing as shown by a reduction in local scar tissue and painresponses. Systemic effects may be noted by a patient's reaction such ashot flashes, chills, low-grade fever, or mineral salt cravings within ashort time period after receiving injections if nutrient levels in theextra-cellular matrix are low.

Glutathione is a known antioxidant, but it also has residence on twocysteine residues within fibroblast growth factors, in particular FGF-2(Mueller and Fusenig 2011). The invention shows that modulation of FGFactivity is glutathione dependent, as low levels of glutathione preventa healing response that is permanent. Therefore, the synergetic effectsof pitcher plant and glutathione are needed for Cytenssic therapyinjections.

According to some embodiments, the present invention features ananti-inflammatory composition suitable for parenteral administration(i.e. intramuscular, subcutaneous or intravenous injections) fortreating inflammation. Said composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, one or more vitamins at a range of about 0.001% to25% w/vol of the composition, one or more minerals at a range of about0.001% to 25% w/vol of the composition, and one or more amino acids at arange of about 0.001% to 25% w/vol of the composition. Without wishingto limit the invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said vitamins, minerals, and amino acids into cells,thereby reducing inflammation.

In some embodiments, the one or more vitamins are niacin, folic acid, ora combination thereof. In further embodiments, the one or more vitaminscan include retinoic acid, vitamin B-complex, vitamin C, vitamin D,vitamin E, vitamin K, and/or derivatives thereof. In preferredembodiments, the one or more minerals are magnesium, selenium, zinc or acombination thereof. Other examples of said minerals include, but arenot limited to, calcium, phosphorus, sodium, potassium, chloride,sulfur, iron, manganese, copper, iodine, cobalt, and fluoride. In otherembodiments, the amino acid is L-cysteine or L-arginine. In furtherembodiments, the composition may comprise glutathione at a range ofabout 0.001% to 25% w/vol of the composition. In an exemplaryembodiment, the vitamin may be niacin, the minerals are magnesium,selenium, and zinc, said vitamin, minerals and glutathione are presentat a ratio of about 15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1selenium:0.5-1 niacin.

In yet another embodiment, the present invention features ananti-inflammatory composition suitable for parenteral administration(i.e. intramuscular, subcutaneous or intravenous injections) fortreating inflammation. The composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, about 0.001% to 25% w/vol of niacin, about 0.001% to25% w/vol of magnesium, about 0.001% to 25% w/vol of selenium, about0.001% to 25% w/vol of zinc, about 0.001% to 25% w/vol of L-cysteine,and about 0.001% to 25% w/vol of glutathione. Without wishing to limitthe invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said niacin, magnesium, selenium, zinc, L-cysteine,and glutathione into cells, thereby reducing inflammation. Furtherstill, the composition is effective for stimulating movement andactivity of fibroblasts cells, increasing fibroblast growth factorslevels, and adjusting fibrinogen levels to homeostatic levels, therebyreducing inflammation.

Any of the injectable anti-inflammatory compositions described hereinmay comprise the herbal preparation of the carnivorous plant preparedfrom a Sarracenia species, a Nepenthes species, a Dionaea species, anUtricularia species, a Heliamphora species, a Cephalotus species, or aDrosera species. For example, the herbal preparation of the carnivorousplant may be prepared from Sarracenia flava, Sarracenia purpurea, ormixed hybrids thereof.

In some embodiments, any of the anti-inflammatory composition describedherein may further comprise one or more plant preparations at a range ofabout 0.1-99% vol of the composition. The plant preparations may be anastragalus preparation, a curcumin preparation, a black cohoshpreparation, an Orchidaceae plant preparation, a Lilium plantpreparation, a Sanguinaria canadensis preparation, a Rosa plantpreparation, cannabidiol (CBD) derived from a hemp plant preparation ora berry preparation. In other embodiments, the anti-inflammatorycomposition may further comprise one or more solutions at a range ofabout 0.1-99% vol of the composition. The one or more solutions may be awitch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, or a gelatin. In still otherembodiments, the composition may further comprise one or moresupplements at a range of about 0.001-25% w/vol of the composition,wherein the one or more supplements are essential fatty acids,glucosamine, or a combination thereof.

In an exemplary embodiment, the injectable anti-inflammatory compositionmay comprise one or more plant preparations at a range of about 0.1-99%vol of the composition, wherein the one or more plant preparations areselected from a group consisting of an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol; about 0.001% to 25% w/vol of niacin;about 0.001% to 25% w/vol of magnesium; about 0.001% to 25% w/vol ofselenium; about 0.001% to 25% w/vol of zinc; about 0.001% to 25% w/volof L-cysteine; about 0.001% to 25% w/vol of glutathione. The compositionmay optionally comprise an herbal preparation of a pitcher plant at arange of about 0.1% to 99% vol of the composition. The pitcher plant maybe Sarracenia flava, Sarracenia purpurea, or mixed hybrids thereof. In apreferred embodiment, the ratio ofmagnesium:glutathione:zinc:selenium:niacin in the composition is about15-25:2-8:0.5-1:0.5-1:0.5-1. Without wishing to limit the invention to aparticular theory or mechanism, the composition can be effective forincreasing fibroblast growth factors levels, adjusting fibrinogen levelsto homeostatic levels, and stimulating movement and activity offibroblasts cells, thereby reducing inflammation. In a furtherembodiment, the anti-inflammatory composition may further comprise oneor more solutions at a range of about 0.1-99% vol of the composition.For example, the solutions may be a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin.

According to another embodiment, the present invention may feature ananti-inflammatory composition suitable for parenteral administration(i.e. intramuscular, subcutaneous or intravenous injections) andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition. In one embodiment, the anti-inflammatory composition mayfurther comprise one or more vitamins, such as niacin, folic acid, or acombination thereof, at a range of about 0.001% to 25% w/vol of thecomposition. In another embodiment, the anti-inflammatory compositionmay further comprise one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In yet another embodiment, the anti-inflammatorycomposition may further comprise one or more amino acids, such asL-cysteine or L-arginine, at a range of about 0.001% to 25% w/vol of thecomposition. In a further embodiment, the anti-inflammatory compositionmay comprise glutathione at a range of about 0.001% to 25% w/vol of thecomposition. For example, the anti-inflammatory composition may compriseniacin, magnesium, selenium, zinc, and glutathione at a ratio of about15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1 selenium:0.5-1 niacin.

In another embodiment, the present invention may feature ananti-inflammatory composition suitable for parenteral administration(i.e. intramuscular, subcutaneous or intravenous injections) andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition in combination with at least one other component. The othercomponent may be the one or more vitamins, the one or more minerals, theone or more amino acids, or glutathione. Without wishing to limit theinvention to a particular theory or mechanism, the herbal preparation ofthe carnivorous plant is effective for increasing cellular uptake of theother component (i.e. vitamins, minerals, amino acids, or glutathione)into cells, thereby reducing inflammation.

In some embodiments, the number of components in combination with theherbal preparation of the carnivorous plant can range from 1 to 4components. For example, the composition may comprise the herbalpreparation of the carnivorous plant and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the herbal preparation of the carnivorous plant and one or moreminerals, such as magnesium, selenium, zinc or a combination thereof, ata range of about 0.001% to 25% w/vol of the composition. In anotherembodiment, the composition may comprise the herbal preparation of thecarnivorous plant and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the herbalpreparation of the carnivorous plant and glutathione at a range of about0.001% to 25% w/vol of the composition.

In one embodiment, the herbal preparation of the carnivorous plant maybe combined with two components, such as for example: vitamins andminerals, or vitamins and amino acids, or vitamins and glutathione, ormineral and amino acids, or minerals and glutathione, or amino acids andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In another embodiment, the herbal preparation of the carnivorous plantmay be combined with three components, such as for example: vitamins,minerals, and amino acids; or vitamins, minerals, and glutathione; ormineral, amino acids, and glutathione. The amount of the other componentmay each be at a range of about 0.001% to 25% w/vol of the composition.

In a further embodiment, the anti-inflammatory composition may compriseone or more plant preparations at a range of about 0.1-99% vol of thecomposition. Examples of said plant preparations include, but are notlimited to, a curcumin preparation, an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol. In yet a further embodiment, theanti-inflammatory composition may comprise one or more solutions at arange of about 0.1-99% vol of the composition. Examples of saidsolutions include, but are not limited to, a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin. In another embodiment, theanti-inflammatory composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

According to some embodiments, the present invention may feature ananti-inflammatory composition suitable for parenteral administration(i.e. intramuscular, subcutaneous or intravenous injections) andeffective for treating inflammation, comprising a plant preparation at arange of about 0.1% to 100% vol of the composition, wherein the plantpreparation is selected from a group consisting of an Orchidaceae plantpreparation, a Lilium plant preparation, a Rosa plant preparation, and ahemp plant preparation containing cannabidiol; one or more vitamins,such as niacin, folic acid, or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; one or more minerals, suchas magnesium, selenium, zinc or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; and one or more aminoacids, such as L-cysteine or L-arginine, at a range of about 0.001% to25% w/vol of the composition. In some embodiments, the anti-inflammatorycomposition may further comprise glutathione at a range of about 0.001%to 25% w/vol of the composition.

In some embodiments, the number of components in combination with theplant preparation can range from 1 to 4 components. For example, thecomposition may comprise the plant preparation at a range of about 0.1%to 100% vol of the composition; and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the plant preparation at a range of about 0.1% to 100% vol ofthe composition, and one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In another embodiment, the composition may comprisethe plant preparation at a range of about 0.1% to 100% vol of thecomposition, and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the plantpreparation at a range of about 0.1% to 100% vol of the composition, andglutathione at a range of about 0.001% to 25% w/vol of the composition.

In one embodiment, the plant preparation may be combined with twocomponents, such as for example: vitamins and minerals, or vitamins andamino acids, or vitamins and glutathione, or mineral and amino acids, orminerals and glutathione, or amino acids and glutathione. The amount ofthe other component may each be at a range of about 0.001% to 25% w/volof the composition.

In another embodiment, the plant preparation may be combined with threecomponents, such as for example: vitamins, minerals, and amino acids; orvitamins, minerals, and glutathione; or mineral, amino acids, andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In other embodiments, the injectable anti-inflammatory composition mayfurther comprise an herbal preparation of a pitcher plant at a range ofabout 0.1% to 99% vol of the composition. In a preferred embodiment, thepitcher plant is Sarracenia flava, Sarracenia purpurea, or mixed hybridsthereof. In a further embodiment, the anti-inflammatory composition maycomprise one or more solutions at a range of about 0.1-99% vol of thecomposition. Examples of said solutions include, but are not limited to,a witch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, and a gelatin. In anotherembodiment, the composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

Transdermal Effect

In other embodiments, Cytenssic therapy involves the pitcher plantcombined with any topical agent designed to soothe or heal the skin frominflammatory, arthritic or cancerous conditions. Inflammatory healingreactions involve the transformation of fibroblasts into myofibroblasts.The myofibroblasts use a high amount of the fibrin from fibrinogen, andare only active for acute conditions. However, if the inflammationcontinues for long periods of time, myofibroblasts stay in the area,which is commonly the case for cancerous tumors and metastasis (Muellerand Fusenig 2011).

The term “skin” means the keratinous surfaces skin, hair and nails. Theterm “skin” when used herein is in the broad sense meaning the skin ofthe face, body, feet, neck, etc. The term “topical composition” as usedherein shall mean the complete product including the active components,the carrier, and any adjuvants, thickeners, excipients, etc. asdescribed herein which is applied to a person's skin.

Generally in the practice of methods of the invention, the topicalcomposition is topically applied to the skin areas, such as that of theface, arms, legs, feet, and hand, at predetermined or as-needed regimeneither at intervals by application of a moisturizer, toner, lotion,cream, or gel, it generally being the case that gradual improvement isnoted with each successive application. Insofar as has been determinedbased upon clinical studies to date, no adverse side effects areencountered.

According to another embodiment, the present invention features atopical composition comprising an herbal preparation of a pitcher plant.In one embodiment, the herbal preparation of the pitcher plant is at arange of about 1% to 99% volume of the composition. The composition maybe effective in reducing inflammation and stimulating movement andactivity of fibroblasts. In some embodiments, the topical formulationmay be in prepared as a viscous emulsion, such as a lotion, cream, oil,balm or gel. In preferred embodiments, the pitcher plant is Sarraceniaflava, Sarracenia purpurea, or hybrids thereof. Sarracenia flava issupposedly toxic since it contains the neurotoxin, coniine. However,contrary to popular belief, the present invention has discovered thattopically administration of the Sarracenia flava preparation to mammalsis safe and can induce healing effects.

In some embodiments, the topical composition may further compriseglutathione at a range of about 0.1-99% vol of the topical composition.In other embodiments, the composition may further comprise one or moreof the following: aloe vera gel, glycerine, natural oils, an emulsifier,menthol crystals, berries, green tea extract, medicinal mushrooms,turmeric, ginger, viscum, burdock, devil's claw, boneset, valerian,skullcap, marshmallow root, mullein leaf, elecampane root, fennel seed,licorice root, old man's beard lichen, orange peel, osha root, wildcherry bark, propolis, ginkgo, poppy, polygonum, hops, passionflower,avena, and arnica.

In other embodiments, the topical composition may further comprise atherapeutically effective amount of one or more plant preparations, at arange of about 0.1-99% vol of the topical composition, selected from agroup consisting of an astragalus preparation, a curcumin preparation, ablack cohosh preparation, an Orchidaceae plant preparation, a Liliumplant preparation, a Sanguinaria canadensis preparation, a Rosa plantpreparation, cannabidiol (CBD) derived from a hemp plant preparation,and a berry preparation. The berry preparation may be an antioxidant.The Orchidaceae plant preparation may be a fibroblast protector. TheLilium plant preparation may be a fibroblast motility enhancer.

In still other embodiments, the topical composition may further compriseone or more solutions, at a range of about 0.1-99% vol of the topicalcomposition. Examples of the one or more solutions include, but are notlimited to, a witch hazel solution for astringing the tissues, clay fordrawing out toxins, a lye solution for producing soap products foradditional cleansing, a salt solution such as epsom salts for mineralbalance, carrier oils such as coconut oil, olive oil, castor oil, canolaoil, sweet almond oil, apricot kernel oil, avocado oil, grapeseed oil,jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, and eveningprimrose oil, and a gelatin.

In yet other embodiments, the topical formulation may further compriseone or more supplements, at a range of about 0.1-20% weight/vol (w/v) ofthe topical composition, selected from a group consisting of vitamins,minerals, essential fatty acids, amino acids, and amine derivatives. Thevitamins may be selected from a group consisting of retinoic acid,niacin, folic acid, vitamin B-complex, vitamin C, vitamin D, vitamin E,vitamin K, and/or derivatives thereof. The minerals may be selected froma group consisting of calcium, phosphorus, magnesium, sodium, potassium,chloride, sulfur, iron, manganese, copper, iodine, zinc, cobalt,fluoride, selenium, and pharmaceutically acceptable salts. The aminederivative may be glucosamine. The amino acid may be a cysteine or anarginine.

Without wishing to limit the invention to a particular theory ormechanism, it has been surprisingly discovered that when appliedtopically, the herbal preparation of the pitcher plant creates atransdermal effect, i.e. the herbal preparation of the pitcher plant candeliver substances across and through the skin. For instance, magnesiumis a mineral that is typically insoluble in fats. When magnesium wascombined with the herbal preparation of the pitcher plant, specificallya pitcher plant infused oil, magnesium was able to dissolve in theherbal preparation of the pitcher plant. Hence, substances, such asminerals, vitamins, and others that are insoluble in fats, can beadministered topically via the herbal preparation of the pitcher plant.For example, when the herbal preparation of the pitcher plant, incombination with vitamins and minerals, is administered topically on thesubject's skin, the subject will then taste the vitamins and minerals inhis or her mouth because the pitcher plant transports the vitamins andminerals through the skin and to the fibroblasts, which are stimulatedinto movement by the pitcher plant.

According to some embodiments, the present invention features ananti-inflammatory composition suitable for topical administration fortreating inflammation. Said composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, one or more vitamins at a range of about 0.001% to25% w/vol of the composition, one or more minerals at a range of about0.001% to 25% w/vol of the composition, and one or more amino acids at arange of about 0.001% to 25% w/vol of the composition. Without wishingto limit the invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said vitamins, minerals, and amino acids into cells,thereby reducing inflammation.

In some embodiments, the one or more vitamins are niacin, folic acid, ora combination thereof. In further embodiments, the one or more vitaminscan include retinoic acid, vitamin B-complex, vitamin C, vitamin D,vitamin E, vitamin K, and/or derivatives thereof. In preferredembodiments, the one or more minerals are magnesium, selenium, zinc or acombination thereof. Other examples of said minerals include, but arenot limited to, calcium, phosphorus, sodium, potassium, chloride,sulfur, iron, manganese, copper, iodine, cobalt, and fluoride. In otherembodiments, the amino acid is L-cysteine or L-arginine. In furtherembodiments, the composition may comprise glutathione at a range ofabout 0.001% to 25% w/vol of the composition. In an exemplaryembodiment, the vitamin may be niacin, the minerals are magnesium,selenium, and zinc, said vitamin, minerals and glutathione are presentat a ratio of about 15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1selenium:0.5-1 niacin.

In yet another embodiment, the present invention features ananti-inflammatory composition suitable for topical administration fortreating inflammation. The composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, about 0.001% to 25% w/vol of niacin, about 0.001% to25% w/vol of magnesium, about 0.001% to 25% w/vol of selenium, about0.001% to 25% w/vol of zinc, about 0.001% to 25% w/vol of L-cysteine,and about 0.001% to 25% w/vol of glutathione. Without wishing to limitthe invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said niacin, magnesium, selenium, zinc, L-cysteine,and glutathione into cells, thereby reducing inflammation. Furtherstill, the composition is effective for stimulating movement andactivity of fibroblasts cells, increasing fibroblast growth factorslevels, and adjusting fibrinogen levels to homeostatic levels, therebyreducing inflammation.

Any of the topical anti-inflammatory compositions described herein maycomprise the herbal preparation of the carnivorous plant prepared from aSarracenia species, a Nepenthes species, a Dionaea species, anUtricularia species, a Heliamphora species, a Cephalotus species, or aDrosera species. For example, the herbal preparation of the carnivorousplant may be prepared from Sarracenia flava, Sarracenia purpurea, ormixed hybrids thereof.

In some embodiments, any of the anti-inflammatory composition describedherein may further comprise one or more plant preparations at a range ofabout 0.1-99% vol of the composition. The plant preparations may be anastragalus preparation, a curcumin preparation, a black cohoshpreparation, an Orchidaceae plant preparation, a Lilium plantpreparation, a Sanguinaria canadensis preparation, a Rosa plantpreparation, cannabidiol (CBD) derived from a hemp plant preparation ora berry preparation. In other embodiments, the anti-inflammatorycomposition may further comprise one or more solutions at a range ofabout 0.1-99% vol of the composition. The one or more solutions may be awitch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, or a gelatin. In still otherembodiments, the composition may further comprise one or moresupplements at a range of about 0.001-25% w/vol of the composition,wherein the one or more supplements are essential fatty acids,glucosamine, or a combination thereof.

In an exemplary embodiment, the topical anti-inflammatory compositionmay comprise one or more plant preparations at a range of about 0.1-99%vol of the composition, wherein the one or more plant preparations areselected from a group consisting of an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol; about 0.001% to 25% w/vol of niacin;about 0.001% to 25% w/vol of magnesium; about 0.001% to 25% w/vol ofselenium; about 0.001% to 25% w/vol of zinc; about 0.001% to 25% w/volof L-cysteine; about 0.001% to 25% w/vol of glutathione. The compositionmay optionally comprise an herbal preparation of a pitcher plant at arange of about 0.1% to 99% vol of the composition. The pitcher plant maybe Sarracenia flava, Sarracenia purpurea, or mixed hybrids thereof. In apreferred embodiment, the ratio ofmagnesium:glutathione:zinc:selenium:niacin in the composition is about15-25: 2-8:0.5-1:0.5-1:0.5-1. Without wishing to limit the invention toa particular theory or mechanism, the composition can be effective forincreasing fibroblast growth factors levels, adjusting fibrinogen levelsto homeostatic levels, and stimulating movement and activity offibroblasts cells, thereby reducing inflammation. In a furtherembodiment, the anti-inflammatory composition may further comprise oneor more solutions at a range of about 0.1-99% vol of the composition.For example, the solutions may be a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin.

According to another embodiment, the present invention may feature ananti-inflammatory composition suitable for topical administration andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition. In one embodiment, the anti-inflammatory composition mayfurther comprise one or more vitamins, such as niacin, folic acid, or acombination thereof, at a range of about 0.001% to 25% w/vol of thecomposition. In another embodiment, the anti-inflammatory compositionmay further comprise one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In yet another embodiment, the anti-inflammatorycomposition may further comprise one or more amino acids, such asL-cysteine or L-arginine, at a range of about 0.001% to 25% w/vol of thecomposition. In a further embodiment, the anti-inflammatory compositionmay comprise glutathione at a range of about 0.001% to 25% w/vol of thecomposition. For example, the anti-inflammatory composition may compriseniacin, magnesium, selenium, zinc, and glutathione at a ratio of about15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1 selenium:0.5-1 niacin.

In another embodiment, the present invention may feature ananti-inflammatory composition suitable for topical administration andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition in combination with at least one other component. The othercomponent may be one or more vitamins, one or more minerals, one or moreamino acids, or glutathione. Without wishing to limit the invention to aparticular theory or mechanism, the herbal preparation of thecarnivorous plant is effective for increasing cellular uptake of theother component (i.e. vitamins, minerals, amino acids, or glutathione)into cells, thereby reducing inflammation.

In some embodiments, the number of components in combination with theherbal preparation of the carnivorous plant can range from 1 to 4components. For example, the composition may comprise the herbalpreparation of the carnivorous plant and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the herbal preparation of the carnivorous plant and one or moreminerals, such as magnesium, selenium, zinc or a combination thereof, ata range of about 0.001% to 25% w/vol of the composition. In anotherembodiment, the composition may comprise the herbal preparation of thecarnivorous plant and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the herbalpreparation of the carnivorous plant and glutathione at a range of about0.001% to 25% w/vol of the composition.

In one embodiment, the herbal preparation of the carnivorous plant maybe combined with two components, such as for example: vitamins andminerals, or vitamins and amino acids, or vitamins and glutathione, ormineral and amino acids, or minerals and glutathione, or amino acids andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In another embodiment, the herbal preparation of the carnivorous plantmay be combined with three components, such as for example: vitamins,minerals, and amino acids; or vitamins, minerals, and glutathione; ormineral, amino acids, and glutathione. The amount of the other componentmay each be at a range of about 0.001% to 25% w/vol of the composition.

In a further embodiment, the anti-inflammatory composition may compriseone or more plant preparations at a range of about 0.1-99% vol of thecomposition. Examples of said plant preparations include, but are notlimited to, a curcumin preparation, an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol. In yet a further embodiment, theanti-inflammatory composition may comprise one or more solutions at arange of about 0.1-99% vol of the composition. Examples of saidsolutions include, but are not limited to, a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin. In another embodiment, theanti-inflammatory composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

According to some embodiments, the present invention may feature ananti-inflammatory composition suitable for topical administration andeffective for treating inflammation, comprising a plant preparation at arange of about 0.1% to 100% vol of the composition, wherein the plantpreparation is selected from a group consisting of an Orchidaceae plantpreparation, a Lilium plant preparation, a Rosa plant preparation, and ahemp plant preparation containing cannabidiol; one or more vitamins,such as niacin, folic acid, or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; one or more minerals, suchas magnesium, selenium, zinc or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; and one or more aminoacids, such as L-cysteine or L-arginine, at a range of about 0.001% to25% w/vol of the composition. In some embodiments, the anti-inflammatorycomposition may further comprise glutathione at a range of about 0.001%to 25% w/vol of the composition.

In some embodiments, the number of components in combination with theplant preparation can range from 1 to 4 components. For example, thecomposition may comprise the plant preparation at a range of about 0.1%to 100% vol of the composition; and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the plant preparation at a range of about 0.1% to 100% vol ofthe composition, and one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In another embodiment, the composition may comprisethe plant preparation at a range of about 0.1% to 100% vol of thecomposition, and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the plantpreparation at about 0.1% to 100% vol of the composition, andglutathione at about 0.001% to 25% w/vol of the composition.

In one embodiment, the plant preparation may be combined with twocomponents, such as for example: vitamins and minerals, or vitamins andamino acids, or vitamins and glutathione, or mineral and amino acids, orminerals and glutathione, or amino acids and glutathione. The amount ofthe other component may each be at a range of about 0.001% to 25% w/volof the composition.

In another embodiment, the plant preparation may be combined with threecomponents, such as for example: vitamins, minerals, and amino acids; orvitamins, minerals, and glutathione; or mineral, amino acids, andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In other embodiments, the anti-inflammatory composition may furthercomprise an herbal preparation of a pitcher plant at a range of about0.1% to 99% vol of the composition. In a preferred embodiment, thepitcher plant is Sarracenia flava, Sarracenia purpurea, or mixed hybridsthereof. In a further embodiment, the anti-inflammatory composition maycomprise one or more solutions at a range of about 0.1-99% vol of thecomposition. Examples of said solutions include, but are not limited to,a witch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, and a gelatin. In anotherembodiment, the composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

Generally, topical application to skin tissue is accomplished inassociation with a dermatologically acceptable carrier, and particularlyone in which the components are soluble or are effectively solubilized(e.g., as an emulsion or microemulsion). Where employed, the carrier isinert, non-toxic, and does not bring about any adverse effect on theskin areas to which it is applied. As noted, these ingredients can beformulated into a cream, lotion, oil, balm or gel, or a solid stick, byutilization of different proportions of the ingredients and/or byinclusion of thickening agents such as gums or other forms ofhydrophilic colloids. One possible embodiment includes lotions, creams,and gels, which are referred to herein as dermally or dermatologicallyacceptable carriers, and are formulated using conventional techniquesknown to those of ordinary skill in the art.

Topical administration of any of the compositions described herein maybe applied once, twice, or multiple times per day, or as prescribed bythe physician, to one or more specific areas on the body i.e. arms,legs, feet, and the like. One of ordinary skill in the art can preparethe topical composition to contain a desired dose of vitamins, minerals,amino acids, and glutathione to create a healing and anti-inflammatoryeffect. In some embodiments, the amount of components may be varied,i.e. increased or decreased, as required to treat inflammation. Forexample, the dosage of vitamins, minerals, glutathione, and/or aminoacids may be increased from an initial dosage if testing determines thatadditional amounts are required. The dosage may then be decreased aftera period of use and when the inflammation has been reduced or cured.

Oral Administration

Likewise, oral administration may be implemented for internal support.According to one embodiment, the present invention features an oralcomposition comprising an herbal preparation of a pitcher plant. In oneembodiment, the herbal preparation is a pitcher plant tincture having analcohol to water volumetric ratio of about 50:50 to 60:40. Preferably,the pitcher plant is a Sarracenia flava, Sarracenia purpurea, or hybridsthereof. Without wishing to limit the invention to a particular theoryor mechanism, the present invention has discovered that, contrary topopular belief, oral administration of the Sarracenia flava preparationis safe and can induce healing effects. For instance, the oralcomposition may be effective for decreasing fibrinogen levels.

In alternative embodiments, the oral composition may further compriseherbs such as orchids for anti-senescence fibroblastic support or lilyextracts for enhanced fibroblast motility. Oral administration of thecomposition may also be anti-inflammatory when the pitcher plant iscombined with herbs such as curcumin or black cohosh. Astragalus may becombined with the pitcher plant for cytoprotective effects, or berriesfor additional antioxidant effects. In some embodiments, the oralcomposition may be administered to the subject at a dose of about 1-2tsp per day or 1 Tbsp per day for two months in order to decreasefibrinogen to homeostatic levels.

According to some embodiments, the present invention features ananti-inflammatory composition suitable for oral administration fortreating inflammation. Said composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, one or more vitamins at a range of about 0.001% to25% w/vol of the composition, one or more minerals at a range of about0.001% to 25% w/vol of the composition, and one or more amino acids at arange of about 0.001% to 25% w/vol of the composition. Without wishingto limit the invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said vitamins, minerals, and amino acids into cells,thereby reducing inflammation.

In some embodiments, the one or more vitamins are niacin, folic acid, ora combination thereof. In further embodiments, the one or more vitaminscan include retinoic acid, vitamin B-complex, vitamin C, vitamin D,vitamin E, vitamin K, and/or derivatives thereof. In preferredembodiments, the one or more minerals are magnesium, selenium, zinc or acombination thereof. Other examples of said minerals include, but arenot limited to, calcium, phosphorus, sodium, potassium, chloride,sulfur, iron, manganese, copper, iodine, cobalt, and fluoride. In otherembodiments, the amino acid is L-cysteine or L-arginine. In furtherembodiments, the composition may comprise glutathione at a range ofabout 0.001% to 25% w/vol of the composition. In an exemplaryembodiment, the vitamin may be niacin, the minerals are magnesium,selenium, and zinc, said vitamin, minerals and glutathione are presentat a ratio of about 15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1selenium:0.5-1 niacin.

In yet another embodiment, the present invention features ananti-inflammatory composition suitable for oral administration fortreating inflammation. The composition may comprise an herbalpreparation of a carnivorous plant at a range of about 0.1% to 100% volof the composition, about 0.001% to 25% w/vol of niacin, about 0.001% to25% w/vol of magnesium, about 0.001% to 25% w/vol of selenium, about0.001% to 25% w/vol of zinc, about 0.001% to 25% w/vol of L-cysteine,and about 0.001% to 25% w/vol of glutathione. Without wishing to limitthe invention to a particular theory or mechanism, the herbalpreparation of the carnivorous plant is effective for increasingcellular uptake of said niacin, magnesium, selenium, zinc, L-cysteine,and glutathione into cells, thereby reducing inflammation. Furtherstill, the composition is effective for stimulating movement andactivity of fibroblasts cells, increasing fibroblast growth factorslevels, and adjusting fibrinogen levels to homeostatic levels, therebyreducing inflammation.

Any of the oral anti-inflammatory compositions described herein maycomprise the herbal preparation of the carnivorous plant prepared from aSarracenia species, a Nepenthes species, a Dionaea species, anUtricularia species, a Heliamphora species, a Cephalotus species, or aDrosera species. For example, the herbal preparation of the carnivorousplant may be prepared from Sarracenia flava, Sarracenia purpurea, ormixed hybrids thereof.

In some embodiments, any of the anti-inflammatory composition describedherein may further comprise one or more plant preparations at a range ofabout 0.1-99% vol of the composition. The plant preparations may be anastragalus preparation, a curcumin preparation, a black cohoshpreparation, an Orchidaceae plant preparation, a Lilium plantpreparation, a Sanguinaria canadensis preparation, a Rosa plantpreparation, cannabidiol (CBD) derived from a hemp plant preparation ora berry preparation. In other embodiments, the anti-inflammatorycomposition may further comprise one or more solutions at a range ofabout 0.1-99% vol of the composition. The one or more solutions may be awitch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, or a gelatin. In still otherembodiments, the composition may further comprise one or moresupplements at a range of about 0.001-25% w/vol of the composition,wherein the one or more supplements are essential fatty acids,glucosamine, or a combination thereof.

In an exemplary embodiment, the oral anti-inflammatory composition maycomprise one or more plant preparations at a range of about 0.1-99% volof the composition, wherein the one or more plant preparations areselected from a group consisting of an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol; about 0.001% to 25% w/vol of niacin;about 0.001% to 25% w/vol of magnesium; about 0.001% to 25% w/vol ofselenium; about 0.001% to 25% w/vol of zinc; about 0.001% to 25% w/volof L-cysteine; about 0.001% to 25% w/vol of glutathione. The compositionmay optionally comprise an herbal preparation of a pitcher plant at arange of about 0.1% to 99% vol of the composition. The pitcher plant maybe Sarracenia flava, Sarracenia purpurea, or mixed hybrids thereof. In apreferred embodiment, the ratio ofmagnesium:glutathione:zinc:selenium:niacin in the composition is about15-25: 2-8:0.5-1:0.5-1:0.5-1. Without wishing to limit the invention toa particular theory or mechanism, the composition can be effective forincreasing fibroblast growth factors levels, adjusting fibrinogen levelsto homeostatic levels, and stimulating movement and activity offibroblasts cells, thereby reducing inflammation. In a furtherembodiment, the anti-inflammatory composition may further comprise oneor more solutions at a range of about 0.1-99% vol of the composition.For example, the solutions may be a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin.

According to another embodiment, the present invention may feature ananti-inflammatory composition suitable for oral administration andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition. In one embodiment, the anti-inflammatory composition mayfurther comprise one or more vitamins, such as niacin, folic acid, or acombination thereof, at a range of about 0.001% to 25% w/vol of thecomposition. In another embodiment, the anti-inflammatory compositionmay further comprise one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In yet another embodiment, the anti-inflammatorycomposition may further comprise one or more amino acids, such asL-cysteine or L-arginine, at a range of about 0.001% to 25% w/vol of thecomposition. In a further embodiment, the anti-inflammatory compositionmay comprise glutathione at a range of about 0.001% to 25% w/vol of thecomposition. For example, the anti-inflammatory composition may compriseniacin, magnesium, selenium, zinc, and glutathione at a ratio of about15-25 magnesium:2-8 glutathione:0.5-1 zinc:0.5-1 selenium:0.5-1 niacin.

In another embodiment, the present invention may feature ananti-inflammatory composition suitable for oral administration andeffective for treating inflammation, comprising an herbal preparation ofa carnivorous plant at a range of about 0.1% to 100% vol of thecomposition in combination with at least one other component. The othercomponent may be the one or more vitamins, the one or more minerals, theone or more amino acids, or glutathione. Without wishing to limit theinvention to a particular theory or mechanism, the herbal preparation ofthe carnivorous plant is effective for increasing cellular uptake of theother component (i.e. vitamins, minerals, amino acids, or glutathione)into cells, thereby reducing inflammation.

In some embodiments, the number of components in combination with theherbal preparation of the carnivorous plant can range from 1 to 4components. For example, the composition may comprise the herbalpreparation of the carnivorous plant and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the herbal preparation of the carnivorous plant and one or moreminerals, such as magnesium, selenium, zinc or a combination thereof, ata range of about 0.001% to 25% w/vol of the composition. In anotherembodiment, the composition may comprise the herbal preparation of thecarnivorous plant and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the herbalpreparation of the carnivorous plant and glutathione at a range of about0.001% to 25% w/vol of the composition.

In one embodiment, the herbal preparation of the carnivorous plant maybe combined with two components, such as for example: vitamins andminerals, or vitamins and amino acids, or vitamins and glutathione, ormineral and amino acids, or minerals and glutathione, or amino acids andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In another embodiment, the herbal preparation of the carnivorous plantmay be combined with three components, such as for example: vitamins,minerals, and amino acids; or vitamins, minerals, and glutathione; ormineral, amino acids, and glutathione. The amount of the other componentmay each be at a range of about 0.001% to 25% w/vol of the composition.

In a further embodiment, the anti-inflammatory composition may compriseone or more plant preparations at a range of about 0.1-99% vol of thecomposition. Examples of said plant preparations include, but are notlimited to, a curcumin preparation, an Orchidaceae plant preparation, aLilium plant preparation, a Rosa plant preparation, and a hemp plantpreparation containing cannabidiol. In yet a further embodiment, theanti-inflammatory composition may comprise one or more solutions at arange of about 0.1-99% vol of the composition. Examples of saidsolutions include, but are not limited to, a witch hazel solution, a lyesolution, a salt solution, clay, coconut oil, olive oil, castor oil,canola oil, sweet almond oil, apricot kernel oil, avocado oil, grapeseedoil, jojoba oil, sunflower oil, hemp seed oil, kukui nut oil, eveningprimrose oil, and a gelatin. In another embodiment, theanti-inflammatory composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

According to some embodiments, the present invention may feature ananti-inflammatory composition suitable for oral administration andeffective for treating inflammation, comprising a plant preparation at arange of about 0.1% to 100% vol of the composition, wherein the plantpreparation is selected from a group consisting of an Orchidaceae plantpreparation, a Lilium plant preparation, a Rosa plant preparation, and ahemp plant preparation containing cannabidiol; one or more vitamins,such as niacin, folic acid, or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; one or more minerals, suchas magnesium, selenium, zinc or a combination thereof, at a range ofabout 0.001% to 25% w/vol of the composition; and one or more aminoacids, such as L-cysteine or L-arginine, at a range of about 0.001% to25% w/vol of the composition. In some embodiments, the anti-inflammatorycomposition may further comprise glutathione at a range of about 0.001%to 25% w/vol of the composition.

In some embodiments, the number of components in combination with theplant preparation can range from 1 to 4 components. For example, thecomposition may comprise the plant preparation at a range of about 0.1%to 100% vol of the composition; and one or more vitamins, such asniacin, folic acid, or a combination thereof, at a range of about 0.001%to 25% w/vol of the composition. As another example, the composition maycomprise the plant preparation at a range of about 0.1% to 100% vol ofthe composition, and one or more minerals, such as magnesium, selenium,zinc or a combination thereof, at a range of about 0.001% to 25% w/volof the composition. In another embodiment, the composition may comprisethe plant preparation at a range of about 0.1% to 100% vol of thecomposition, and one or more amino acids, such as L-cysteine orL-arginine, at a range of about 0.001% to 25% w/vol of the composition.In a further embodiment, the composition may comprise the plantpreparation at a range of about 0.1% to 100% vol of the composition, andglutathione at a range of about 0.001% to 25% w/vol of the composition.

In one embodiment, the plant preparation may be combined with twocomponents, such as for example: vitamins and minerals, or vitamins andamino acids, or vitamins and glutathione, or mineral and amino acids, orminerals and glutathione, or amino acids and glutathione. The amount ofthe other component may each be at a range of about 0.001% to 25% w/volof the composition.

In another embodiment, the plant preparation may be combined with threecomponents, such as for example: vitamins, minerals, and amino acids; orvitamins, minerals, and glutathione; or mineral, amino acids, andglutathione. The amount of the other component may each be about 0.001%to 25% w/vol of the composition.

In other embodiments, the oral anti-inflammatory composition may furthercomprise an herbal preparation of a pitcher plant at a range of about0.1% to 99% vol of the composition. In a preferred embodiment, thepitcher plant is Sarracenia flava, Sarracenia purpurea, or mixed hybridsthereof. In a further embodiment, the anti-inflammatory composition maycomprise one or more solutions at a range of about 0.1-99% vol of thecomposition. Examples of said solutions include, but are not limited to,a witch hazel solution, a lye solution, a salt solution, clay, coconutoil, olive oil, castor oil, canola oil, sweet almond oil, apricot kerneloil, avocado oil, grapeseed oil, jojoba oil, sunflower oil, hemp seedoil, kukui nut oil, evening primrose oil, and a gelatin. In anotherembodiment, the composition may further comprise one or moresupplements, such as essential fatty acids, glucosamine, or acombination thereof, at a range of about 0.001-20% w/vol of thecomposition.

Drop Therapy

In alternative embodiments, the herbal preparation of the pitcher plantmay be used in acupuncture. The acupuncture needle is dipped in theherbal preparation of the pitcher plant, and if desired, with anothertincture/essential oil, before using the needle in the acupunctureprocess. This treatment is known as drop therapy. Non-limiting examplesof essential oils include turmeric, mint, rosemary, cinnamon,frankincense, and basil. For example, patients with sinus infectionswill clear the infection better with the drop therapy than justacupuncture alone. Without wishing to limit the invention to aparticular theory or mechanism, the pitcher plant act can decreasefibrinogen levels to homeostatic levels locally around the insertionsite of the acupuncture needle. In addition, fibroblast movementactivity and movement is stimulated. In other embodiments, whenadministering the composition via injection, the injection needle may bedipped in the herbal preparation of the pitcher plant, and if desired,with another tincture/essential oil, prior to injecting the needle. Infurther embodiments, drop therapy can feature sublingually administeringthe herbal preparation of the pitcher plant, and if desired, withanother tincture/essential oil.

Burnables

In an alternative embodiment, the pitcher plant may be used in candlesand incense. The dried pitcher plant material or the pitcher plantpreparation may be used in the candles or incense. For example, apitcher plant tincture may be immersed into wax such as soy or beeswax.Alternatively, the wax can be infused with the pitcher plant component.

In another alternative embodiment, the pitcher plant may be smoked by asubject. Smoking of the pitcher plant may be effective for instilling amild, relaxing mood in the subject. In one embodiment, the dried plantmaterial of the pitcher plant may be smoked directly. In anotherembodiment, a pitcher plant infused oil may be used in a vaporizingdevice. Without wishing to limit the invention to a particular theory ormechanism, a limonene component and/or a cannabinoid component of thepitcher plant can induce an anxiolytic effect in the subject.

In some embodiments, any of the aforementioned compositions may alsotreat insomnia. The compositions may affect how a person sleeps throughthe night since it is well-documented that the cytokine Interleukin 6(IL-6), which can stimulate inflammatory and auto-immune processes inmany diseases, is active in people with insomnia. As a non-limitingexample, a formula with herbs may contain black cohosh or other herbsthat lower IL-6 to obtain anti-insomnia properties.

EXAMPLES

The following are non-limiting examples of the present invention.

Example 1: Oral Administration

-   -   1. A patient is prescribed to take an oral formulation of an        herbal preparation of the pitcher plant, at a dosage of 1 Tbsp,        twice/day, for 3 weeks.    -   2. Re-test fibrinogen levels.    -   3. Depending on fibrinogen levels, the patient is prescribed a        maintenance dose of ½ to 1 Tbsp/day until fibrinogen levels        decrease to normal levels.

Example 2: Administration by Injection

-   -   1. Draw patient FGF-23 labs.    -   2. Perform spinal injections of 75/25% pitcher plant to        glutathione. Use a 30 g ½ inch needle applied right below the        spinous processes, into the Du meridian acupuncture points,        du14-2. The physician can inject at all points or at key points        such as 14, 11, 10, 6, 4 and 2, depending on how much scar        tissue it felt by the physician and how much injected fluid can        be tolerated by the patient. The physician can start with 9 cc        total and at other visits, may go up to 18 cc along the spine.    -   3. Do monthly injections, ideally every 4 weeks, to allow for        time to heal between and see the symptoms change.    -   4. Check the FGF-23 levels at intervals decided by the physician        and patient.

Example 3: A 39-year old female patient was suffering from fatigue. Thephysician prescribed a topical cream of vitamins and the herbalpreparation of the pitcher plant. The patient reported that she appliedthe topical cream on her abdomen. Within a few hours, she got flushed asthough she took orally a large dose of multi-vitamins or B-complex. Thepatient reported that she has great energy after taking the topicalcream.

Example 4: A female patient suffers from fibromyalgia. Pre-labs of thepatient reported a fibrinogen activity of 326 mg/dL. The patient smokes1 pack of cigarettes per day. Smoking is known to increase fibrinogen.The physician prescribed 1 Tbsp, twice/day of S. purpurea tincture60/40. The patient continued to smoke cigarettes while taking thetincture. Post-labs taken 11 days later reported that the fibrinogenactivity decreased to 261 mg/dL.

Example 5: Pre-labs of a male patient shows a fibrinogen activity of 366mg/dL. Thirty-nine days later, the patient ate copious amount of sugaryfoods during the holidays, and increased his fibrinogen activity to 404mg/dL. Sugar is known to increase fibrinogen. Two months later, thepatient was suffering from painful irritable bowel syndrome. Hisabdominal inflammation is further aggravated by eating sugar. Hisfibrinogen activity increased to 418 mg/dL. His physician prescribed adose of 1 Tbsp, twice/day of the pitcher plant tincture. Forty dayslater, the patient reported that his abdominal pain decreasedsignificantly, as did the fibrinogen. His post-lab fibrinogen activitydecreased to 357 mg/dL.

Example 6: A 50-year old female has the genes for cervical cancer. Thepatient's PAP test results reported: “Atypical squamous cells ofundetermined significance, favor low grade lesion. This latter wouldcorrespond to mild dysplasia and/or HPV effect.” The patient's physicianprescribed a vaginal cream of the topical composition to be appliednightly, unless the patient was menstruating. Seven months later, asecond PAP test of the patient reported: “Negative for intraepitheliallesion or malignancy. Benign cellular changes with reactive features.”The patient no longer has precancerous cells.

Example 7: A female patient suffered from the starting phases ofdementia, osteoarthritis, fibromyalgia and IBS. Pre-labs of the patientreported an FGF-23 level of 99 Ru/mL. The FGF-23 level indicates thatthe patient is a slow-healer. The patient's physician prescribed aseries of injections of the composition at varying ratios, usually75/25% pitcher plant to glutathione. Labs taken 4 months later reportedan increase in FGF-23 levels to 534 Ru/mL. The patient reported that hermemory was returning and that she no longer suffered from fibromyalgiaand IBS pain. Furthermore, her osteoarthritis was also diminishing.

Example 8: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical composition comprising about 5-20 ml of pitcher plant infusedoil of any kind, about 0.2-0.8 g of magnesium, about 0.2-0.8 g ofcalcium, about 0.1-0.5 g of selenium, about 0.05-0.25 g of zinc, andabout 0.8-1.2 g of B-complex is in the form of a cream.

Example 9: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical cream comprising about 5-20 ml of pitcher plant infused oil ofany kind, about 0.001-1 g of niacin, about 0.01-1 g of selenium, about0.01-1 g of zinc, about 0.01-20 g of magnesium, about 0.01-10 g ofglutathione, and about 0.001 to 0.1 g of cysteine is in the form of acream.

Example 10: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical composition comprising about 5-20 ml of pitcher plant infusedoil of any kind, about 0.01-10 g of glutathione, and about 5-10 ml ofaloe vera extract is in the form of a gel or lotion.

Example 11: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical composition comprising about 5-20 ml of pitcher plant infusedoil of any kind, about 0.01-10 g of glutathione, about 1-5 ml of CBDoil, and about 1-5 ml of Rose oil is in the form of a gel or lotion.

Example 12: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical composition, in cream form, comprises about 5-20 ml of pitcherplant infused oil of any kind, about 5-20 ml of CBD oil containing 25%wt/vol of CBDs, about 0.001-1 g of niacin, about 0.01-1 g of selenium,about 0.01-1 g of zinc, about 0.01-20 g of magnesium, about 0.01-10 g ofglutathione, and about 0.001 to 0.1 g of vitamin D is in the form of acream.

Example 13: The following is non-limiting example of a topicalcomposition according to an embodiment of the present invention.

A topical composition comprising about 5-20 ml of pitcher plant infusedoil of any kind, about 5-20 ml of CBD oil containing 25% wt/vol of CBDs,about 0.001-1 g of niacin, about 0.001 to 0.1 g of vitamin D, about0.01-1 g of selenium, about 0.01-1 g of zinc, about 0.01-20 g ofmagnesium, about 0.01-10 g of glutathione, and about 0.001 to 0.1 g ofcysteine is in the form of a cream.

Example 14: The following is non-limiting example of an oral compositionaccording to an embodiment of the present invention.

An oral composition comprising about 5-20 ml of pitcher plant infusedoil of any kind, about 0.001-1 g of niacin, about 0.01-1 g of selenium,about 0.01-1 g of zinc, about 0.01-20 g of magnesium, about 0.01-10 g ofglutathione, and about 1-5 ml of CBD oil is administered orally in pillform or by a dropper.

As used herein, the term “about” refers to plus or minus 10% of thereferenced number.

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the invention. Each reference cited in the present applicationis incorporated herein by reference in its entirety.

Although there has been shown and described the preferred embodiment ofthe present invention, it will be readily apparent to those skilled inthe art that modifications may be made thereto which do not exceed thescope of the appended claims. Therefore, the scope of the invention isonly to be limited by the following claims. In some embodiments, thefigures presented in this patent application are drawn to scale,including the angles, ratios of dimensions, etc. In some embodiments,the figures are representative only and the claims are not limited bythe dimensions of the figures. In some embodiments, descriptions of theinventions described herein using the phrase “comprising” includesembodiments that could be described as “consisting of”, and as such thewritten description requirement for claiming one or more embodiments ofthe present invention using the phrase “consisting of” is met.

What is claimed:
 1. An anti-inflammatory formulation comprising: a. about 0.1-99% wt/vol of a hemp plant preparation containing cannabidiol; b. at least about 0.1% wt/vol of an herbal plant preparation of Sarracenia flava, Sarracenia purpurea, or mixed hybrids thereof; c. at least about 0.001% wt/vol of a mineral component; and d. at least about 0.001% wt/vol of glutathione, wherein the herbal preparation of Sarracenia flava, Sarracenia purpurea, or mixed hybrids thereof is effective for increasing cellular uptake of the mineral component and glutathione into cells, thereby reducing inflammation.
 2. The formulation of claim 1, wherein the hemp plant preparation comprises about 1-30% wt/vol of cannabidiol.
 3. The formulation of claim 1, wherein the hemp plant preparation further comprises about 0.1-20% wt/vol of tetrahydrocannabinol.
 4. The formulation of claim 1, wherein the mineral is selected from a group consisting of magnesium, manganese, selenium, and zinc.
 5. The formulation of claim 1 further comprising one or more vitamins selected from a group consisting of vitamin D, niacin, and folic acid.
 6. The formulation of claim 1 further comprising arnica.
 7. The formulation of claim 1, wherein the formulation is in a form of a lotion, cream, oil, gel, or an oral tincture. 